CA3111702C - METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT - Google Patents

METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT

Info

Publication number
CA3111702C
CA3111702C CA3111702A CA3111702A CA3111702C CA 3111702 C CA3111702 C CA 3111702C CA 3111702 A CA3111702 A CA 3111702A CA 3111702 A CA3111702 A CA 3111702A CA 3111702 C CA3111702 C CA 3111702C
Authority
CA
Canada
Prior art keywords
cells
deacetyltanghinin
mcm
17beta
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
CA3111702A
Other languages
English (en)
French (fr)
Other versions
CA3111702A1 (en
Inventor
Ziyi Wang
Chun Liang
Zhihong Jiang
Zhiling Yu
Jingrong Wang
Liping BAI
Original Assignee
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong University of Science and Technology, Hong Kong Baptist University HKBU, Macau University of Science and Technology filed Critical Hong Kong University of Science and Technology
Publication of CA3111702A1 publication Critical patent/CA3111702A1/en
Application granted granted Critical
Publication of CA3111702C publication Critical patent/CA3111702C/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
CA3111702A 2012-05-09 2013-05-09 METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT Withdrawn - After Issue CA3111702C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
US61/644,442 2012-05-09
CA2873283A CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2873283A Division CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Publications (2)

Publication Number Publication Date
CA3111702A1 CA3111702A1 (en) 2013-11-14
CA3111702C true CA3111702C (en) 2025-03-18

Family

ID=49551267

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3111702A Withdrawn - After Issue CA3111702C (en) 2012-05-09 2013-05-09 METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT
CA2873283A Active CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2873283A Active CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Country Status (9)

Country Link
US (1) US11648258B2 (https=)
EP (2) EP2846807B1 (https=)
JP (6) JP2015517500A (https=)
CN (2) CN104736157B (https=)
AU (1) AU2013259486B2 (https=)
CA (2) CA3111702C (https=)
ES (1) ES2949335T3 (https=)
IN (1) IN2014MN02513A (https=)
WO (1) WO2013169989A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN108948119B (zh) * 2017-05-19 2023-11-21 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
CN114177189A (zh) * 2019-03-27 2022-03-15 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
AU2001282088A1 (en) * 2000-08-17 2002-02-25 Terness, Peter Immunosuppressive, antiinflammatory and analgetic compounds
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
EP1755649A1 (en) * 2004-04-14 2007-02-28 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
JP2008525479A (ja) * 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
EP1787645A1 (en) * 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
CN101683359B (zh) * 2008-09-28 2012-05-09 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法
WO2010068247A1 (en) * 2008-12-10 2010-06-17 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
EP2846807A4 (en) 2016-07-27
JP2024001049A (ja) 2024-01-09
US20150099712A1 (en) 2015-04-09
JP2018100274A (ja) 2018-06-28
EP4248978A3 (en) 2023-11-08
CN104736157B (zh) 2019-06-11
EP2846807C0 (en) 2023-06-07
JP2021193132A (ja) 2021-12-23
IN2014MN02513A (https=) 2015-07-17
WO2013169989A1 (en) 2013-11-14
EP4248978A2 (en) 2023-09-27
ES2949335T3 (es) 2023-09-27
JP2025169320A (ja) 2025-11-12
CA3111702A1 (en) 2013-11-14
CN110412285A (zh) 2019-11-05
EP2846807A1 (en) 2015-03-18
JP2020073544A (ja) 2020-05-14
CN110412285B (zh) 2022-11-15
CA2873283C (en) 2021-05-04
AU2013259486B2 (en) 2019-12-12
US11648258B2 (en) 2023-05-16
AU2013259486A1 (en) 2014-12-18
CA2873283A1 (en) 2013-11-14
JP2015517500A (ja) 2015-06-22
CN104736157A (zh) 2015-06-24
EP2846807B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
De et al. Plumbagin from a tropical pitcher plant (Nepenthes alata Blanco) induces apoptotic cell death via a p53-dependent pathway in MCF-7 human breast cancer cells
JP2024001049A (ja) Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
Lee et al. EGCG induces apoptosis in human laryngeal epidermoid carcinoma Hep2 cells via mitochondria with the release of apoptosis-inducing factor and endonuclease G
Das et al. Mahanine, A dietary phytochemical, represses mammary tumor burden in rat and inhibits subtype regardless breast cancer progression through suppressing self-renewal of breast cancer stem cells
Clement et al. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53
Guan et al. Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation
Xu et al. In vitro and in vivo antitumor effects of plant-derived miliusanes and their induction of cellular senescence
Li et al. Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U2OS cells
Li et al. The effect of dihydroartemisinin on the malignancy and epithelial-mesenchymal transition of gastric cancer cells
Guo et al. Ginsengenin derivatives synthesized from 20 (R)-panaxotriol: Synthesis, characterization, and antitumor activity targeting HIF-1 pathway
Wang et al. Liquiritigenin inhibits the migration, invasion, and EMT of prostate cancer through activating ER stress
Liu et al. A combined phytochemistry and network pharmacology approach to reveal potential anti-NSCLC effective substances and mechanisms in Marsdenia tenacissima (roxb.) moon (stem)
CN109496153B (zh) 作为肝细胞癌治疗剂的龙葵皂苷b及其衍生物
Han et al. A new semisynthetic 1-O-acetyl-6-O-lauroylbritannilactone induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway
US20230293564A1 (en) Method and compounds for inhibiting the MCM complex and their application in cancer treatment
HK40100635A (en) Method and compounds for inhibiting the mcm complex and their application in cancer treatment
Liu et al. LingZhi oligopeptides amino acid sequence analysis and anticancer potency evaluation
Goswami et al. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells
HK40016841B (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40016841A (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
Fallit et al. Targeting FOXP3 in glioblastoma: Blockade of tumor intrinsic effects boosts response to chemo-radiotherapy
KR102943670B1 (ko) 오미자 유래 화합물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
US9895345B2 (en) Use of Lappaol F to inhibit tumor cell growth
WO2017122736A1 (ja) 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210310

AZWI Withdrawn application

Effective date: 20210611

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240725

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240919

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250220

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250313

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250502

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260418